Claris Biotherapeutics, Inc. filed an amended Form D with the Securities and Exchange Commission on 2026-08-07.
Claris Biotherapeutics, Inc. filed an amended Form D notice of an exempt securities offering with the SEC on August 7, 2026. The filing reports $55.74M sold. Its industry group is Biotechnology. It names Stephen Brady (Executive Officer, Director), Reza Dana (Director), Kenneth Harrison (Director) (SEC Form D/A, August 7, 2026).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like Claris Biotherapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-08-07 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Claris Biotherapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Claris Biotherapeutics, Inc., from the filings we hold.
Biotechnology raises by companies based in California, filed in August 2026, largest first.
Get an email when Claris Biotherapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Claris Biotherapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Claris Biotherapeutics, Inc. →Get the full cited report on Claris Biotherapeutics, Inc.
What the filing shows about Claris Biotherapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Claris Biotherapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Claris Biotherapeutics, Inc.'s address as 475 Magellan Ave, Half Moon Bay, CA 94019.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Claris Biotherapeutics, Inc. →
Amended on 2026-08-12: proceeds used for payments to executive officers, directors or promoters changed from $0 to $3,100,000. Figures on this page are from the amendment. Amended filing · Original filing
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Claris Biotherapeutics, Inc. See pricing
Claris Biotherapeutics, Inc. is a registered filer with the SEC (CIK 1809726) and has filed since 2024-01-08. 4 filings are on record, the latest on 2026-08-07.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Claris Biotherapeutics, Inc.'s Form D of 2026-08-07 names Stephen Brady, Reza Dana, Kenneth Harrison and 9 more as its officers, directors or promoters.
Its new offerings report $71.34M sold across 4 offerings, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 766 filings in Biotechnology, totalled by week. The dot is this raise, $55.74M, on the same scale — one filing against the whole group's total, so it sits low by construction.
This estimate is based on the expected time period for R&D/related activities to be funded by the proceeds set forth in Item 13(b) above and the aggregate regular/continuing compensation for these individuals? services during that period
Stephen Brady is named as Executive Officer and Director on the Form D that Claris Biotherapeutics, Inc. filed with the SEC on 7 August 2026, one of 12 people that filing names.
Reza Dana is named as Director on the Form D that Claris Biotherapeutics, Inc. filed with the SEC on 7 August 2026, one of 12 people that filing names.
Kenneth Harrison is named as Director on the Form D that Claris Biotherapeutics, Inc. filed with the SEC on 7 August 2026, one of 12 people that filing names.
Marc de Garidel is named as Director on the Form D that Claris Biotherapeutics, Inc. filed with the SEC on 7 August 2026, one of 12 people that filing names.
Meredith Fisher is named as Director on the Form D that Claris Biotherapeutics, Inc. filed with the SEC on 7 August 2026, one of 12 people that filing names.
Henry Rath is named as Executive Officer on the Form D that Claris Biotherapeutics, Inc. filed with the SEC on 7 August 2026, one of 12 people that filing names.
Susan Orr is named as Executive Officer on the Form D that Claris Biotherapeutics, Inc. filed with the SEC on 7 August 2026, one of 12 people that filing names.
Michael Dybbs is named as Director on the Form D that Claris Biotherapeutics, Inc. filed with the SEC on 7 August 2026, one of 12 people that filing names.
Matt Hobson is named as Director on the Form D that Claris Biotherapeutics, Inc. filed with the SEC on 7 August 2026, one of 12 people that filing names.
Maha Radhakrishnan is named as Director on the Form D that Claris Biotherapeutics, Inc. filed with the SEC on 7 August 2026, one of 12 people that filing names.
Clarke Atwell is named as Executive Officer on the Form D that Claris Biotherapeutics, Inc. filed with the SEC on 7 August 2026, one of 12 people that filing names.
Brian Baum is named as Executive Officer on the Form D that Claris Biotherapeutics, Inc. filed with the SEC on 7 August 2026, one of 12 people that filing names.
12 people named on the filing — 5 holding an executive role and 7 as directors only.
Named as of the 2026-08-07 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Claris Biotherapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Claris Biotherapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Claris Biotherapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Claris Biotherapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Claris Biotherapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Claris Biotherapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: The rest of the US raises, week of 2026-08-03 · Biotech raises, week of 2026-08-03
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/claris-biotherapeutics-inc-form-d-26000001